HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

February 28, 2021

Study Completion Date

February 28, 2021

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

HepaSphere/QuadraSphere Microspheres

HepaSphere/QuadraSphere Microspheres loaded with doxorubicin

PROCEDURE

PVA, lipiodol, doxorubicin

Conventional TACE procedure using PVA, lipiodol and doxorubicin

Trial Locations (23)

3000

University Hospitals K.U. Leuven (Dept of Hematology), Leuven

10029

Mount Sinai Medical Center, New York

12100

S. Croce e Carle Hospital, Cuneo

12208

Albany Medical Center, Albany

15261

VA Pittsburgh Healthcare System, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

19141

Albert Einstein Healthcare, Philadelphia

20007

Georgetown University Hospital, Washington D.C.

29425

MUSC Medical Center (Medical University of South Carolina), Charleston

33075

Hospital Saint Andre, Bordeaux

33606

Tampa General Hospital, Tampa

35209

University of Alabama at Birmingham, Birmingham

Massachusetts General Hospital, Boston

60611

Northwestern University, Chicago

72205

Greater Arkansas Veterans Healthcare, Little Rock

78229

UT Health and Science Center, San Antonio

85711

Tuscon Medical Center, Tucson

90073

VA Greater Los Angeles Healthcare System, Los Angeles

90095

UCLA, Los Angeles

94304

Palo Alto Veterans Institute for Research, Palo Alto

94305

Stanford University, Stanford

94804

Hospital Paul Brousse, Villejuif

115 28

Evgenidion University Hospital, Athens

Sponsors
All Listed Sponsors
lead

Merit Medical Systems, Inc.

INDUSTRY